Recombinant micro-exon gene 3 (MEG-3) antigens from Schistosoma mansoni failed to induce protection against infection but show potential for serological diagnosis

•vaccination with MEG-3.2 or MEG-3.4 activates humoral and cellular response in mice.•vaccination with MEG-3.2 or MEG-3.4 fails to reduce parasite burden and liver pathology in infected mice.•MEG-3.2 distinguishes infected from non-infected individuals, showing diagnostic potential. Sequence databas...

Full description

Saved in:

Bibliographic Details
Published in:	Acta tropica Vol. 204; p. 105356
Main Authors:	Mambelli, F.S., Figueiredo, B.C., Morais, S.B., Assis, N.R.G., Fonseca, C.T., Oliveira, S.C.
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 01-04-2020
Subjects:	Diagnosis MEG Schistosomiasis Vaccine Schistosomiasis Vaccine Diagnosis MEG
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	•vaccination with MEG-3.2 or MEG-3.4 activates humoral and cellular response in mice.•vaccination with MEG-3.2 or MEG-3.4 fails to reduce parasite burden and liver pathology in infected mice.•MEG-3.2 distinguishes infected from non-infected individuals, showing diagnostic potential. Sequence databases on Schistosoma mansoni have revealed micro-exon gene (MEGs) families. Many of these genes are highly expressed in parasite life cycle stages associated with the mammalian host infection and appear to be involved in immune evasion by schistosomes. So, we believe that MEG-coding proteins would make potential candidates for vaccine development or diagnosis for schistosomiasis. Here, we study MEG-3.2 and MEG-3.4, members of the MEG-3 family. Recombinant (r) proteins were produced and formulated with Freund's adjuvant for vaccination of mice. Immunization with recombinant MEG-3.2 or MEG-3.4 formulation generated high levels of IgG1 antibodies. Additionally, vaccination also induced a mixed Th1/Th2/Th17-type of response, since IFN-γ, IL-5 and IL-17 cytokines were detected in the supernatant of spleen cell cultures; however it failed to induce reduction in parasitic worm burden. Finally, the recombinant proteins were evaluated in a serological assay using human samples. Schistosome-infected individuals showed higher levels of both IgG and IgM against rMEG-3.2 compared to non-infected individuals, while only IgM anti-rMEG-3.4 antibodies were elevated in infected patients. Therefore, between both studied molecules, MEG-3.2 protein is the antigen that shows potential to compose a serological diagnosis test for schistosomiasis.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0001-706X 1873-6254
DOI:	10.1016/j.actatropica.2020.105356